“`html
Johnson & Johnson, a stalwart in the health-care industry, has announced its agreement to acquire Intra-Cellular Therapies Inc. for approximately $14.6 billion. This acquisition comes at a time when health-care dealmaking is regaining momentum following a downturn in 2024. Intra-Cellular is recognized for its innovative treatments for central nervous system disorders, particularly focusing on mental health conditions. This strategic move is poised to bolster J&J’s portfolio in the biopharmaceutical sector, aligning with its broader ambitions to advance treatment options for neurological conditions.
According to a statement released by Johnson & Johnson, the acquisition price has been set at $132 per share, significantly above the recent market valuation of Intra-Cellular, reflecting a 36% increase in early trading following the announcement. This stock price appreciation also represents a 40% increase over the last twelve months, elevating Intra-Cellular’s market value to nearly $10 billion.
The acquisition signifies J&J’s continued investment in expanding its therapeutic offerings, specifically targeting complex neurological and psychiatric disorders. This comes as a part of a broader trend in health-care mergers and acquisitions, which have started to pick up after a notable decline in the previous year. The investment in Intra-Cellular is strategically aligned with the growing demand for advanced mental health solutions and solidifies J&J’s commitment to pioneering effective treatments in the biopharmaceutical field.
“`